Review of Incretin‐Related
Therapies in Diabetes: 2014 Update
The Review of Incretin‐Related Therapies in Diabetes: 2014 Update webcast series reviews the current evidence on the efficacy, safety, and pharmacologic profile of incretin therapies in the prevention and treatment of diabetes and clinical management of diabetes.
Expert faculty critical appraise current research reported in published literature and national meetings and synthesize their implications for treatment, allowing practitioners to enhance their ability to create management strategies for their patients and thus, improve the care of this patient population.
Leann Olansky, MD
Release Date: January 30, 2015
Release Date: December 30, 2014
George Grunberger, MD, FACP, FACE
Release Date: November 25, 2014
- Explain the hormonal and metabolic abnormalities in patients with diabetes and describe the role of incretin mimetics in their correction/amelioration.
- Compare and contrast the efficacy, safety, and pharmacology of incretin therapies for T2DM.
- Appropriately institute strategies to assess risk and manage renal disease in patients with T2DM.
- Implement multifaceted approaches to diabetes therapies that improve monitoring, achievement of therapeutic guidelines, patient adherence, and the overall continuity of care for inpatients and outpatients.
- Appropriately institute strategies to assess risk and manage cardiovascular disease and review evidence for the potential perioperative use of incretin mimetics in coronary bypass surgery and in the treatment of congestive heart failure.
This activity is designed for endocrinologists, family practice and internal medicine practitioners, and other interested health care professionals, including nurse practitioners and physician assistants.
Charles Faiman, MD, FRCPC, MACE
Consultant and Past Chairman
Department of Endocrinology, Diabetes and Metabolism
Endocrinology & Metabolism Institute